Page 1

Dimerix For Immediate Release DIMERIX QUARTERLY ACTIVITIES REPORT Quarter highlights and operational activities • AGM held on 27 September 2021 • Phase 3 global study in FSGS kidney patients commenced with first ethics and regulatory approval • DMX - 200 CLARITY COVID - 19 study expanded into Australia • DMX - 200 CLARITY COVID - 19 study approved in India • Successful $ 4 million Share Purchase Plan closed oversubscribed • Successful $ 20 million Placement to fund phase 3 trials announced • DMX - 200 COVID - 19 study opened more sites in Europe and UK • > 400 patients recruited to the REMAP - CAP RAAS inhibition domain to date • FDA confirmed phase 3 study endpoints in FSGS kidney disease • Cash position of $ 8.7 million at 30 September 2021 ( not including Placement Tranche 2 and SPP funds received in October ) • Net operating cash flow for the September quarter was - $ 4.8 million only For personal use MELBOURNE , Australia , 25 October 2021 : Dimerix Limited ( ASX : DXB ) ( " Dimerix " or the " Company " ) , a clinical - stage biopharmaceutical company with multiple late - stage clinical assets , today announced its Appendix 4C and Quarterly Activities Report for the period ended 30 September 2021. During the quarter , Dimerix made significant operational progress , in line with the strategic plan . Dimerix ended the quarter with cash of $ 8.7 million ( $ 5.3 million at 30 June 2021 ) , with net operating cash outflows for the period of $ 4.8 million , which was in line with company expectations ( $ 3.2 million net operating cash outflows in the prior quarter ) . The increase in total operating cash outflow for the quarter relative to the prior period is a result of increased clinical and manufacturing expenditure . During the quarter , Dimerix received $ 13.7 million relating to the settlement of Tranche 1 and partial settlement of Tranche 2 Placement . Additionally , Dimerix repaid the $ 5 million loan facility held with its major shareholder , Mr Peter Meurs , which had been in place since March 2021 . Dimerix also received $ 10.3 million after the quarter end relating to settlement of the SPP and remaining Tranche 2 allocation , which is not reflected in the 4C - Quartlerly Cashflow . Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs Dimerix HQ 425 Smith St , Fitzroy 3065 Victoria , Australia T. 1300 813 321 E. investor@dimerix.com